CD19 and acute myeloid leukemia: According to data from the original CD19 CAR in the juvenile B‐cell ALL research, the ideal length of CAR‐T cells to prolong remission is up to 8–10 months, which seems unlikely in AML patients given the danger of infection and its possibly fatal consequences.